Clinical Evaluation and Management of Inflammatory Myopathies

Sameer Chhibber; Anthony A. Amato

doi:10.1055/s-0035-1558980

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2015; 35(04): 347-359
DOI: 10.1055/s-0035-1558980

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Clinical Evaluation and Management of Inflammatory Myopathies

Sameer Chhibber

¹Division of Neurology, Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada

,

Anthony A. Amato

²Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

› Institutsangaben

Abstract

The idiopathic inflammatory myopathies are classified into four distinct subtypes: dermatomyositis, polymyositis, inclusion body myositis, and immunomediated necrotizing myopathy. These subtypes are clinically, histologically, and pathogenically distinct. Dermatomyositis, polymyositis, and necrotizing myopathy generally respond to immunotherapy, whereas inclusion body myositis does not. In this review, the authors focus on the clinical evaluation and management of idiopathic inflammatory myopathies and highlight recent therapeutic studies and the evolving role of myositis-specific antibodies.

Keywords

inflammatory myositis - inclusion body myositis - dermatomyositis - immunomediated necrotizing myopathy

Volltext

Referenzen

References
1 Amato AA, Greenberg SA. Inflammatory myopathies. Continuum (Minneap Minn) 2013; 19 (6 Muscle Disease): 1615-1633
2 Distad BJ, Amato AA, Weiss MD. Inflammatory myopathies. Curr Treat Options Neurol 2011; 13 (2) 119-130
3 Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007; 69 (21) 2008-2019
4 Tansley SL, McHugh NJ. Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies. Curr Rheumatol Rep 2014; 16 (12) 464
5 Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62 (9) 2757-2766
6 Mammen AL, Chung T, Christopher-Stine L , et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63 (3) 713-721
7 Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS ONE 2011; 6 (5) e20266
8 Limaye V, Luke C, Tucker G , et al. The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 2013; 33 (4) 965-971
9 Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326 (6) 363-367
10 Yang Z, Lin F, Qin B, Liang Y, Zhong R. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 2015; 42 (2) 282-291
11 Olazagasti JM, Baez PJ, Wetter DA, Ernste FC. Cancer risk in dermatomyositis: a meta-analysis of cohort studies. Am J Clin Dermatol 2015; 16 (2) 89-98
12 Ponyi A, Constantin T, Garami M , et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 2005; 1051: 64-71
13 Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford) 2015; 54 (1) 50-63
14 Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292 (8) 403-407
15 Brown Jr RH, Amato A. Calpainopathy and eosinophilic myositis. Ann Neurol 2006; 59 (6) 875-877
16 Jethwa H, Jacques TS, Gunny R, Wedderburn LR, Pilkington C, Manzur AY. Limb girdle muscular dystrophy type 2B masquerading as inflammatory myopathy: case report. Pediatr Rheumatol Online J 2013; 11 (1) 19
17 Fardet L, Rybojad M, Gain M , et al. Incidence, risk factors, and severity of herpesvirus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm. Arch Dermatol 2009; 145 (8) 889-893
18 Naffaa ME, Bishara R, Braun-Moscovici Y, Balbir-Gurman A. Unusual sequelae of adult-onset dermatomyositis. BMJ Case Rep 2014; 2014: bcr-2014-bcr-204521
19 Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371 (9631) 2201-2212
20 Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 2009; 80 (10) 1060-1068
21 Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54 (4) 597-613
22 Khan S, Christopher-Stine L. Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features. Rheum Dis Clin North Am 2011; 37 (2) 143-158 , v v
23 Lega JC, Fabien N, Reynaud Q , et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 2014; 13 (9) 883-891
24 Liu WC, Ho M, Koh WP , et al. An 11-year review of dermatomyositis in Asian patients. Ann Acad Med Singapore 2010; 39 (11) 843-847
25 Mohassel P, Mammen AL. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve 2013; 48 (4) 477-483
26 Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41 (2) 185-190
27 Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005; 165 (22) 2671-2676
28 Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 2009; 80 (11) 1186-1193
29 Dimachkie MM, Barohn RJ. Inclusion body myositis. Neurol Clin 2014; 32 (3) 629-646 , vii vii
30 Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56 (4) 255-286
31 Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985; 12 (6) 1140-1148
32 Amato AA, Gronseth GS, Jackson CE , et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996; 40 (4) 581-586
33 Quinn C, Salameh JS, Smith T, Souayah N. Necrotizing myopathies: an update. J Clin Neuromuscul Dis 2015; 16 (3) 131-140
34 Goodwin DW. Imaging of skeletal muscle. Rheum Dis Clin North Am 2011; 37 (2) 245-251 , vi–vii vi–vii
35 Charlot-Lambrecht I, Brochot P, Noblet H, Varoquier C, Eschard JP. Neurogenic muscle hypertrophy. Joint Bone Spine 2009; 76 (4) 401-403
36 Finanger EL, Russman B, Forbes SC, Rooney WD, Walter GA, Vandenborne K. Use of skeletal muscle MRI in diagnosis and monitoring disease progression in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am 2012; 23 (1) 1-10 , ix ix
37 Greenberg SA. Cytoplasmic 5′-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility. Muscle Nerve 2014; 50 (4) 488-492
38 Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol 2012; 24 (6) 602-608
39 Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184: 134-153
40 Trallero-Araguás E, Rodrigo-Pendás JA, Selva-O'Callaghan A , et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64 (2) 523-532
41 Gunawardena H, Wedderburn LR, Chinoy H , et al; Juvenile Dermatomyositis Research Group, UK and Ireland. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60 (6) 1807-1814
42 Fiorentino DF, Chung LS, Christopher-Stine L , et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013; 65 (11) 2954-2962
43 Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73 (4) 420-428
44 Hengstman GJ, ter Laak HJ, Vree Egberts WT , et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65 (12) 1635-1638
45 Suzuki S, Hayashi YK, Kuwana M, Tsuburaya R, Suzuki N, Nishino I. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol 2012; 69 (6) 728-732
46 Benveniste O, Drouot L, Jouen F , et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011; 63 (7) 1961-1971
47 Werner JL, Christopher-Stine L, Ghazarian SR , et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012; 64 (12) 4087-4093
48 Mammen AL, Gaudet D, Brisson D , et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 2012; 64 (8) 1233-1237
49 Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16 (2) 193-208
50 Greenberg SA, Pinkus JL, Pinkus GS , et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57 (5) 664-678
51 Greenberg SA, Sanoudou D, Haslett JN , et al. Molecular profiles of inflammatory myopathies. Neurology 2002; 59 (8) 1170-1182
52 Greenberg SA. Sustained autoimmune mechanisms in dermatomyositis. J Pathol 2014; 233 (3) 215-216
53 Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16 (2) 209-215
54 Chung T, Christopher-Stine L, Paik JJ, Corse A, Mammen AL. The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve 2015;
55 Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 1991; 41 (6) 936-939
56 Salajegheh M, Pinkus JL, Taylor JP , et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009; 40 (1) 19-31
57 Nogalska A, Terracciano C, D'Agostino C, King Engel W, Askanas V. p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol 2009; 118 (3) 407-413
58 Greenberg SA. Pathogenesis and therapy of inclusion body myositis. Curr Opin Neurol 2012; 25 (5) 630-639
59 Machado PM, Dimachkie MM, Barohn RJ. Sporadic inclusion body myositis: new insights and potential therapy. Curr Opin Neurol 2014; 27 (5) 591-598
60 Benveniste O, Stenzel W, Hilton-Jones D, Sandri M, Boyer O, van Engelen BG. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol 2015; 129 (5) 611-624
61 Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve 2015; 51 (5) 638-656
62 Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol Rep 2010; 12 (3) 198-203
63 Mammen AL. Necrotizing myopathies: beyond statins. Curr Opin Rheumatol 2014; 26 (6) 679-683
64 Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 2014; 83 (5) 426-433
65 Rose MR ; ENMC IBM Working Group. 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 2013; 23 (12) 1044-1055
66 Lundberg IE, Svensson J. Registries in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2013; 25 (6) 729-734
67 Dimachkie MM, Barohn RJ, Amato AA. Idiopathic inflammatory myopathies. Neurol Clin 2014; 32 (3) 595-628 vii vii
68 Thomas CF. Limper AH. Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients. UpToDate, January 6th 2015. Available at: http://UpToDate.com/contents/treatment-and-prevention-of-pneumocystis-pneumonia-in-non-hiv-infected-patients?source=search_result&search=pcp+prophylaxis&selectedTitle=1%7E51 . Accessed March 6, 2015
69 Giannini M, Callen JP. Treatment of dermatomyositis with methotrexate and prednisone. Arch Dermatol 1979; 115 (10) 1251-1252
70 Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 1980; 92 (3) 365-369
71 Dalakas Illa I MC, Dambrosia JM , et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329 (27) 1993-2000
72 Gelardi C, Paolini L, Danieli MG. Subcutaneous immunoglobulin G in idiopathic inflammatory myopathies: therapeutic implications. Isr Med Assoc J 2014; 16 (10) 646-647
73 Unger L, Kampf S, Lüthke K, Aringer M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology (Oxford) 2014; 53 (9) 1630-1638
74 Nalotto L, Iaccarino L, Zen M , et al. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. Immunol Res 2013; 56 (2–3) 362-370
75 Limaye V, Hissaria P, Liew CL, Koszyka B. Efficacy of rituximab in refractory antisynthetase syndrome. Intern Med J 2012; 42 (3) e4-e7
76 Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010; 62 (9) 1328-1334
77 Oddis CV, Reed AM, Aggarwal R , et al; RIM Study Group Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65 (2) 314-324
78 Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005; 44 (3) 386-389
79 Schneider C, Gold R, Schäfers M, Toyka KV. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002; 25 (2) 286-288
80 Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999; 353 (9166) 1762-1763
81 Mitsui T, Kuroda Y, Kunishige M, Matsumoto T. Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med 2005; 44 (11) 1197-1199
82 Borleffs JC. Cyclosporine as monotherapy for polymyositis?. Transplant Proc 1988; 20 (3, Suppl 4) 333-334
83 Jones DW, Snaith ML, Isenberg DA. Cyclosporine treatment for intractable polymyositis. Arthritis Rheum 1987; 30 (8) 959-960
84 Kono DH, Klashman DJ, Gilbert RC. Successful IV pulse cyclophosphamide in refractory PM in 3 patients with SLE. J Rheumatol 1990; 17 (7) 982-983
85 Leroy JP, Drosos AA, Yiannopoulos DI, Youinou P, Moutsopoulos HM. Intravenous pulse cyclophosphamide therapy in myositis and Sjögren's syndrome. Arthritis Rheum 1990; 33 (10) 1579-1581
86 Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 2011; 50 (7) 1344-1346
87 Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Joint Bone Spine 2011; 78 (4) 431-432
88 Alexanderson H. Exercise in inflammatory myopathies, including inclusion body myositis. Curr Rheumatol Rep 2012; 14 (3) 244-251
89 Wiesinger GF, Quittan M, Aringer M , et al. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 1998; 37 (2) 196-200
90 Alemo Munters L, Dastmalchi M, Katz A , et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther 2013; 15 (4) R83
91 Alemo Munters L, Dastmalchi M, Andgren V , et al. Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup. Arthritis Care Res (Hoboken) 2013; 65 (12) 1959-1968
92 Alexanderson H, Munters LA, Dastmalchi M , et al. Resistive home exercise in patients with recent-onset polymyositis and dermatomyositis — a randomized controlled single-blinded study with a 2-year followup. J Rheumatol 2014; 41 (6) 1124-1132
93 Alemo Munters L, Alexanderson H, Crofford LJ, Lundberg IE. New insights into the benefits of exercise for muscle health in patients with idiopathic inflammatory myositis. Curr Rheumatol Rep 2014; 16 (7) 429
94 Leff RL, Miller FW, Hicks J, Fraser DD, Plotz PH. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine (Baltimore) 1993; 72 (4) 225-235
95 Barohn RJ, Amato AA, Sahenk Z, Kissel JT, Mendell JR. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995; 45 (7) 1302-1304
96 Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis. Observations in 40 patients. Brain 1989; 112 (Pt 3): 727-747
97 Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48 (3) 712-716
98 Walter MC, Lochmüller H, Toepfer M , et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000; 247 (1) 22-28
99 Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56 (3) 323-327
100 Badrising UA, Maat-Schieman ML, Ferrari MD , et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002; 51 (3) 369-372
101 Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology 2001; 57 (9) 1566-1570
102 Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004; 63 (4) 718-720
103 Barohn RJ, Herbelin L, Kissel JT , et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006; 66 (2, Suppl 1) S123-S124
104 Sancricca C, Mora M, Ricci E, Tonali PA, Mantegazza R, Mirabella M. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci 2011; 32 (5) 841-847
105 Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002; 58 (7) 1081-1087
106 Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci 2013; 334 (1–2) 123-125
107 Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003; 61 (2) 260-262
108 Benveniste O, Guiguet M, Freebody J , et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011; 134 (Pt 11): 3176-3184
109 Amato AA, Sivakumar K, Goyal N , et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 2014; 83 (24) 2239-2246
110 Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med 2003; 35 (1) 31-35
111 Johnson LG, Collier KE, Edwards DJ , et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis 2009; 10 (4) 178-184
112 Spector SA, Lemmer JT, Koffman BM , et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 1997; 20 (10) 1242-1248